Advertisment

biosimilar product

Lupin gets nod for arthritis drug from Canadian health authority
Drug maker Lupin on Tuesday said its biosimilar product Rymti, indicated for the treatment of arthritis, has received approval from the Canadian health authority. The company's
Advertisment
Subscribe